Citi downgraded Hims & Hers to Sell from Neutral with a $25 price target
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims and Hers Health put volume heavy and directionally bearish
- Hims & Hers initiated with a Buy at BTIG
- Hims & Hers price target raised to $24 from $21 at Piper Sandler
- BofA says Hims’ semaglutide compounding opportunity may be shorter than expected
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink